证券代码：300244 证券简称：迪安诊断 公告编号：2025-004 迪安诊断技术集团股份有限公司 2024 年年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 迪安诊断技术集团股份有限公司 董事会 2025 年 4 月 22 日 1 特别提示：本公司 2024 年年度报告及摘要于 2025 年 4 月 23 日在中国证监 会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 迪安诊断技术集团股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第五届董事会第十二次会议，审议通过了《关于<2024 年年度报告>及 <2024 年年度报告摘要>的议案》。为使投资者全面了解公司的经营成果、财务 状况及未来发展规划，公司《2024 年年度报告》及《2024 年年度报告摘要》于 2025 年 4 月 23 日在中国证监会指定的创业板信息披露网站巨潮资讯网上披露， 敬请投资者注意查阅。 巨潮资讯网网址：http://www.cninfo.com.cn/ ...

迪安诊断技术集团股份有限公司 审计委员会对会计师事务所 2024 年度审计履职情况评估及 履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2023 年 12 月修订）》和《公司章程》等规定和要求，迪安诊断技术集团股份有 限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则认真履职。 现 将董事会审计委员会对会计师事务所 2024 年年度审计履行监督职责的情况汇报如 下： 一、会计师事务所基本情况 （一）会计师事务所基本情况 （5）执行事务合伙人：杨志国、朱建弟 截至2024年末，立信拥有合伙人296名、注册会计师2,498名、从业人员总数 10,021名，签署过证券服务业务审计报告的注册会计师743名。立信2024年业务 收入（未经审计）50.01亿元，其中审计业务收入35.16亿元，证券业务收入17.65 亿元。2024年度立信为693家上市公司提供年报审计服务，审计收费 8.54亿元， 同行业上市公司审计客户14家。 （二）聘任会计师事务所履行的程序 2024年4月18日， ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-018 迪安诊断技术集团股份有限公司 关于召开 2024 年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）定于 2025 年 5 月 30 日（星期五）14 点召开 2024 年年度股东大会，本次会议采取现场表决与网络投 票相结合的方式召开，现将有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2024 年年度股东大会 2、会议召集人：公司董事会 公司于 2025 年 4 月 21 日召开的第五届董事会第十二次会议审议通过了《关 于召开 2024 年年度股东大会的议案》。 3、会议召开的合法、合规性： 本次会议议案已经公司第五届董事会第十二次会议、第五届监事会第九次会 议审议通过；本次股东大会会议的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的有关规定。 4、会议召开的日期和时间 （1）现场会议时间：2025 年 5 月 30 日（星期五）14:00 （2）网络投票时间： 通过深圳证券交易所交易系 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-006 迪安诊断技术集团股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 21 日 14 点，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决的方式召开了第五届监事会第九次会议。召开 本次会议的通知已于 2025 年 4 月 11 日以短信、电子邮件等方式通知全体监事。 会议由公司监事会主席师玉鹏先生召集和主持。本次监事会应到监事 3 名，实到 监事 3 名，符合《公司法》和《公司章程》的规定，会议通过了如下决议： 一、审议《关于<2024年度监事会工作报告>的议案》 具体内容详见公司于同日在巨潮资讯网披露的《2024 年度监事会工作报 告》。 该议案尚需提交股东大会审议。 三、审议《关于<2024年年度报告>及<2024年年度报告摘要>的议案》 经审议，监事会认为：公司 2024 年年度报告及摘要的编制和审核符合法律 法规和相关制度的有关规定，报告内容真实、准确、完整的反映了上市公司的财 务状况、经营成果 ...

Financial Performance - The company's overall operating revenue faced pressure due to a slowdown in market demand and intensified industry competition, with a significant impact on profit margins [5]. - The company's operating revenue for 2024 was ¥12,196,223,734.01, a decrease of 9.04% compared to ¥13,408,319,799.56 in 2023 [32]. - The net profit attributable to shareholders for 2024 was -¥357,277,652.58, representing a decline of 216.20% from ¥307,461,061.38 in 2023 [32]. - The cash flow from operating activities for 2024 was ¥1,207,395,648.34, down 37.16% from ¥1,921,354,006.32 in 2023 [32]. - The basic earnings per share for 2024 was -¥0.5790, a decrease of 217.73% compared to ¥0.4918 in 2023 [32]. - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, with a total of -¥380,108,163.92 for 2024 compared to ¥294,754,728.09 in 2023 [32]. - The company reported a total non-operating income of $22.83 million, a significant increase from $12.71 million in 2023, compared to a loss of $194.58 million in 2022 [39]. - The company achieved a revenue of 12.196 billion yuan in the reporting period, a year-on-year decrease of 9.04% [57]. - The net profit attributable to shareholders was -357 million yuan, a year-on-year decline of 216.20% [57]. Strategic Initiatives - The company aims to enhance its core competitiveness through a new five-year strategy focusing on high-quality development, profitability, and healthy cash flow [11]. - The long-term strategy of the company is to become a "technology-driven + data-driven" health medical big data company, focusing on AI and big data applications in the medical field [17]. - The company plans to initiate a new five-year strategic plan in 2025, focusing on becoming a leading provider of integrated medical diagnostic solutions in China [152]. - The strategic implementation will include building a centralized operational system and enhancing digital, automated, and AI technologies [153]. - The company aims to deepen customer engagement and enhance service offerings through a comprehensive value service system [154]. Product Development and Innovation - The company has developed over 4,200 testing projects and has three proprietary product lines, with more than 1,300 products available through its national distribution channels [12]. - The company is exploring new models for integrating precision medicine with closed-loop health management, enhancing personalized service capabilities [14]. - The company achieved a year-on-year revenue growth of 57% in pathogen infection business, 51% in hematological oncology, and 38% in neuroimmunology during the reporting period [62]. - A total of 240 new product evaluations and 287 new testing projects were completed, along with the addition of 25 invention patents and 73 utility model patents [64]. - The company launched the Iris smart regional testing platform, adding 67 collaborative laboratories, with 92% of revenue contribution coming from secondary and above hospitals [65][66]. Market Expansion - The company opened its first overseas laboratory in Vietnam in April, marking a significant step in its internationalization strategy [53]. - The company plans to focus on expanding into Southeast Asia, Central Asia, and the Middle East markets [53]. - The healthcare industry is expected to see a significant increase in demand due to the expansion of grassroots medical resources, creating a market space worth hundreds of billions [44]. Financial Management and Risks - The company has reported uncertainty regarding its ability to continue as a going concern, as indicated by negative net profits over the last three accounting years [32]. - The company is enhancing accounts receivable management to mitigate risks associated with extended customer payment cycles and potential bad debts [168]. - Management risks are highlighted due to rapid business expansion, necessitating improvements in management systems and decision-making efficiency [164]. - The company acknowledges risks related to quality control, emphasizing the need for a robust quality management system to maintain its competitive edge in diagnostic services [163]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements [173]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations [176]. - The company has a dedicated audit committee responsible for overseeing internal and external audits [173]. - The company ensures timely and accurate information disclosure, with designated channels for investor communication [173]. - The company has a clear succession plan in place, ensuring continuity in leadership and strategic direction [187]. Research and Development - R&D investment for 2024 is approximately ¥305.88 million, a decrease of 29.8% from ¥435.56 million in 2023 [107]. - The number of R&D personnel decreased by 24.78% from 807 in 2023 to 607 in 2024 [106]. - The company is focusing on expanding its research and development efforts to innovate new diagnostic solutions [109]. - The company is committed to ongoing research and development to enhance its product offerings and maintain competitive advantage in the market [110]. Customer Engagement and Service - The company emphasizes a customer-centric approach and long-termism to maintain its leading position in the industry [18]. - The company is leveraging a "product + service + digitalization" model to enhance its service capabilities in the healthcare sector [44]. - The company has established a customer reserve pool, adding 1,535 new testing external customers during the reporting period, including 164 tertiary hospitals [61]. Compliance and Quality Control - The company is committed to a compliance management system to mitigate operational risks and ensure sustainable business development [52]. - The company has established a comprehensive quality system based on ISO 15189 standards, with 31 laboratories receiving CNAS accreditation [70]. - The company has received 4 ISO27001 certifications and other privacy security certifications, enhancing its data security management platform [75].

证券代码：300244 证券简称：迪安诊断 公告编号：2025-005 具体内容详见公司于同日在巨潮资讯网披露的《2024 年年度报告》的第三 节"管理层讨论与分析"章节。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议《关于<2024年度董事会工作报告>的议案》 具体内容详见公司于同日在巨潮资讯网披露的《2024 年年度报告》。 第五届独立董事李天天先生、邓泽林先生、蒋斌先生分别向董事会提交了《独 立董事 2024 年度述职报告》，并将在 2024 年年度股东大会上进行述职。 迪安诊断技术集团股份有限公司 表决结果：同意 9 票，反对 0 票，弃权 0 票。 第五届董事会第十二次会议决议公告 该议案尚需提交股东大会审议。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 21 日 19 时，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决的方式召开了第五届董事会第十二次会议。召 开本次会议的通知已于 2025 年 4 月 11 日以短信、电子邮件等方式通知全体董事。 会议由公司董事长陈海斌先生召集 ...

4月9日，迪安诊断今日收盘13.7元，上涨2.85%，最新市净率1.21，总市值85.62亿元。 资金流向方面，4月9日，迪安诊断主力资金净流出33.97万元，近5日总体呈流出状态，5日共流出 9653.84万元。 迪安诊断技术集团股份有限公司的主营业务是医学诊断服务及体外诊断产品销售。公司的主要产品及服 务是医学诊断服务、诊断技术研发、诊断产品生产及销售、CRO、司法鉴定、健康管理。2023年，公 司获得了浙江省人民政府质量奖等荣誉。 最新一期业绩显示，2024年三季报，公司实现营业收入92.58亿元，同比-10.05%；净利润1.31亿元，同 比-75.35%，销售毛利率28.05%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)3迪安诊断-92.5027.851.2185.62亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344.311.4628.16亿4光正眼科-84.88201.676.8418.66亿5创新医疗-78.10-109.142.0337.42亿 ...

Core Viewpoint - The company, Dian Diagnostics, is recognized as a leading third-party medical diagnostics enterprise in China, with a significant accumulation of medical data and a leading position in the application of this data in the healthcare sector [2]. Group 1: Company Performance - As of March 28, 2025, Dian Diagnostics' stock closed at 15.88 yuan, down 1.12%, with a turnover rate of 3.04%, a trading volume of 152,400 shares, and a transaction value of 244 million yuan [1]. - On the same day, the net inflow of main funds was 6.45 million yuan, accounting for 2.64% of the total transaction value [3]. Group 2: Strategic Initiatives - The company is focused on integrating cutting-edge technologies, including robotics and brain-computer interface applications, into its diagnostic services to enhance efficiency and precision for patients [2]. - In 2024, the company repurchased nearly 200 million yuan worth of stock, with plans for stock incentive programs or potential cancellation [2].

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

Summary of the Conference Call Company and Industry - **Company**: Di'an Diagnostics - **Industry**: AI in Medical Diagnostics Key Points and Arguments 1. **AI Medical Business Layout**: Di'an Diagnostics has been focusing on AI in the medical field, particularly in diagnostics and treatment, since 2021 with the establishment of a subsidiary, Yice Technology, specializing in AI pathology [1][2][3] 2. **Product Development**: The company has developed several AI products, including a cervical cancer diagnostic tool that received a Class II medical certification in 2023 and is expected to obtain a Class III certification by June 2023 [3][4] 3. **Market Penetration**: Di'an has signed contracts with approximately 70 local hospitals in Hubei Province, achieving over 50% market share in the digital pathology service system [3][4] 4. **AI Models**: The company has created a proprietary AI model called the Di'an Vertical Model, which is currently under review for official recognition [5][6] 5. **Collaboration with Hospitals**: Di'an collaborates with hospitals, such as Wuhan Union Hospital, to develop predictive models for chronic leukemia treatment, which have gained recognition both domestically and internationally [6][7] 6. **Health Management Initiatives**: Di'an has partnered with Huawei Cloud to enhance health management services, allowing users to upload health reports for risk assessments and personalized recommendations [7][8] 7. **Data Accumulation**: The company has accumulated 5.4 PB of valuable data from approximately 160 million tests conducted annually, with a growth rate of about 100 TB per month [16][17] 8. **Clinical Research Database**: Di'an has launched a clinical research database in collaboration with major hospitals, integrating clinical data with multi-omics data for research purposes [17][18] 9. **Regulatory Compliance**: The company has obtained various certifications for data security and compliance, enhancing its credibility in the data management sector [18][19] 10. **Future Business Opportunities**: Di'an plans to commercialize its AI tools through various channels, including diagnostic testing packages, clinical decision support tools, and smart laboratory products [14][15][20] Additional Important Content 1. **Competitive Landscape**: Di'an acknowledges competition in the AI pathology space, particularly from partnerships like that of Huawei and Ruijin Hospital, but emphasizes its unique data advantages and focus on clinical applications [22][23] 2. **Differentiation in AI Models**: Di'an's AI models are tailored for specific diseases, leveraging extensive data for productization, which sets them apart from competitors focusing on broader applications [24][25] 3. **Market Trends**: The company is observing interest from other provinces in replicating Hubei's digital pathology model, indicating potential for expansion [25][26] 4. **Data Annotation Team**: The company is expanding its data annotation team to manage the increasing volume of data, which is crucial for training AI models [35]